Therapy for Argentine hemorrhagic fever in nonhuman primates with a humanized monoclonal antibody
Open Access
- 8 March 2021
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences of the United States of America
- Vol. 118 (11)
- https://doi.org/10.1073/pnas.2023332118
Abstract
The COVID-19 pandemic has reemphasized the need to identify safe and scalable therapeutics to slow or reverse symptoms of disease caused by newly emerging and reemerging viral pathogens. Recent clinical successes of monoclonal antibodies (mAbs) in therapy for viral infections demonstrate that mAbs offer a solution for these emerging biothreats. We have explored this with respect to Junin virus (JUNV), an arenavirus classified as a category A high-priority agent and the causative agent of Argentine hemorrhagic fever (AHF). There are currently no Food and Drug Administration-approved drugs available for preventing or treating AHF, although immune plasma from convalescent patients is used routinely to treat active infections. However, immune plasma is severely limited in quantity, highly variable in quality, and poses significant safety risks including the transmission of transfusion-borne diseases. mAbs offer a highly specific and consistently potent alternative to immune plasma that can be manufactured at large scale. We previously described a chimeric mAb, cJ199, that provided protection in a guinea pig model of AHF. To adapt this mAb to a format more suitable for clinical use, we humanized the mAb (hu199) and evaluated it in a cynomolgus monkey model of AHF with two JUNV isolates, Romero and Espindola. While untreated control animals experienced 100% lethality, all animals treated with hu199 at 6 d postinoculation (dpi) survived, and 50% of animals treated at 8 dpi survived. mAbs like hu199 may offer a safer, scalable, and more reproducible alternative to immune plasma for rare viral diseases that have epidemic potential.Keywords
Funding Information
- HHS | NIH | National Institute of Allergy and Infectious Diseases (AI111391)
- HHS | NIH | National Institute of Allergy and Infectious Diseases (AI142777)
This publication has 25 references indexed in Scilit:
- Monoclonal antibody therapy for Junin virus infectionProceedings of the National Academy of Sciences of the United States of America, 2016
- Prophylactic and therapeutic testing of Nicotiana-derived RSV-neutralizing human monoclonal antibodies in the cotton rat model.mAbs, 2013
- Junín Virus Pathogenesis and Virus ReplicationViruses, 2012
- Dynamics of brain-derived proteins in cerebrospinal fluidClinica Chimica Acta; International Journal of Clinical Chemistry, 2001
- Junin Virus Monoclonal Antibodies: Characterization and Cross-reactivity with Other ArenavirusesJournal of General Virology, 1989
- Ribavirin prophylaxis and therapy for experimental argentine hemorrhagic feverAntimicrobial Agents and Chemotherapy, 1988
- Virus-specific factors in experimental Argentine hemorrhagic fever in rhesus macaquesJournal of Medical Virology, 1987
- Treatment of Junin Virus‐Infected Guinea Pigs With Immune Serum: Development of Late Neurological DiseaseJournal of Medical Virology, 1986
- IMPORTANCE OF DOSE OF NEUTRALISING ANTIBODIES IN TREATMENT OF ARGENTINE HAEMORRHAGIC FEVER WITH IMMUNE PLASMAThe Lancet, 1984
- Experimental biology and pathogenesis of Junin virus infection in animals and man.1975